p53 gene mutation and expression in naevi and melanomas

Melanoma Research

Volumn 5, Issue 2, 1995, Pages 93-100

  Sparrow, L E ^a   Soong, R ^a   Dawkins, H J S ^a   Iacopetta, B J ^a   Heenan, P J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Immunohistochemistry; Mutation; p53; Tumorigenesis

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; MUTATION; NEVUS; PRIORITY JOURNAL;

BASE SEQUENCE; COMPARATIVE STUDY; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEVUS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN P53; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0028938104     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/00008390-199504000-00004     Document Type: Article

References (42)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
2. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutation in human cancers. Science 1991; 253: 49-53.
3. Vogelstein B, Klinzer KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
4. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Set USA 1992; 89: 7491-7495.
5. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
6. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221.
7. Momand J, Zambetti GP, Olson DC, et al. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992; 69: 1237-1245.
8. Albino A, Fountain J. Molecular genetics of human malignant melanoma. In: Nathanson L, ed. Current Research and Clinical Management of Melanoma. Boston: Kluwer Academic Publishers, 1993: 201-255.
9. Volkenandt M, Schlegel U, Nanus DM, et al. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991; 4: 35-40.
10. Weiss J, Schwechheimer K, Cavanee WK, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 1993; 54: 693-699.
11. Lubbe J, Reichel M, Burg G, et al. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994; 102: 819-821.
12. Florenes VA, Oyjord T, Holm R, et al. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 1994; 69: 253-259.
13. Albino AP, Vidal MJ, McNutt S, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4: 35-45.
14. Stretch J, Gatter KC, Ralfkiaer E, etal. Expression of mutant p53 in melanoma. Cancer Res 1991; 51: 5976-5979.
15. Lassam NJ, From L, Kahn HF. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235-2238.
16. Asklen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer 1992; 52: 13-16.
17. McGregor JM, Yu CCW, Dublin EA, et al. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128: 606-611.
18. Cristofolini M, Boi S, Girlando S, et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993; 129: 739-743.
19. Smith KL, Robbins PD, Dawkins HJS, et al. c-erbB-2 amplification in breast cancer: detection in formal-fixed paraffin embedded tissue by in situ hybridisation. Hum Pathol 1994; 25: 413-418.
20. Yamamoto M, Takahashi H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch A 1993; 422: 127-132.
21. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 1992; 11: 141-148.
22. Hubbert NL, Sedman SA, Schiller JT. Human papilloma virus type 16E6 increases the degradation rate of p53 in human keratinocytes. J Virol 1992; 66: 329-330.
23. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev B, et al. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 1986; 320: 182-185.
24. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993; 29: 741-748.
25. Dei Tos AP, Doglioni C, Laurino L, et al. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology 1993; 22: 45-50.
26. Heyderman E, Dagg B. p53 immunostaining in benign breast disease. Lancet 1991; 338: 1532.
27. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130; 181-186.
28. Hall PA, McKee PH, Menage HDP, et al. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8; 203-207.
29. Dix B, Robbins P, Carrello S, et al. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994; 70: 1-5.
30. Nigro JM, Baker S, Preisinger A, et al. Mutations in the p53 gene occur in diverse tumour types. Nature 1989; 342: 705-708.
31. Albino AP. The role of oncogenes and growth factors in progressive melanoma genesis. Pigment Cell Res 1992; Suppl 2: 199-218.
32. Modzelewski JJR, Park HK, Raso DS, et al. Evaluation of p53, Ki67 and DNA content as prognostic indicators in primary cutaneous and metastatic melanomas. J Lab Invest 1994; 70: 48A.
33. Stone CH, Lynch MD, Kubus J, et al. Correlation of tumor proliferative activity and p53 expression with tumor progression and survival in malignant melanoma. J Lab Invest 1994; 70: 50A.
34. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 240: 912-915.
35. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993; 7: 855-865.
36. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GAD1M5 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
37. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
38. Callahan R, p53 mutations, another breast cancer prognostic factor. JNCI 1992; 84: 826-827.
39. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262-7266.
40. Lane DP, Crawfor LV. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278: 261-263.
41. Sarnow P, Ho YS, Williams J, et al. Adenovirus Elb-58kd tumour antigen and SV40 large tumour antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 1982; 28: 387-394.
42. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degeneration of p53- Cell 1990; 63: 1129-1136.